These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 21090826

  • 1. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 2. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 3. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J.
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [Abstract] [Full Text] [Related]

  • 4. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators.
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [Abstract] [Full Text] [Related]

  • 5. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 6. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J, Varela A.
    Am J Cardiovasc Drugs; 2009 Oct 27; 9 Suppl 1():9-12. PubMed ID: 20000882
    [Abstract] [Full Text] [Related]

  • 7. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS, Le Heuzey JY.
    Am J Ther; 2008 Oct 27; 15(5):461-73. PubMed ID: 18806523
    [Abstract] [Full Text] [Related]

  • 8. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar 27; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 9. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 10. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

  • 11. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
    Prasad UK, Gray D, Purcell H.
    Adv Ther; 2009 Feb 29; 26(2):127-37. PubMed ID: 19259630
    [Abstract] [Full Text] [Related]

  • 12. Focus on ivabradine: a new heart rate-controlling drug.
    Riccioni G.
    Expert Rev Cardiovasc Ther; 2009 Feb 29; 7(2):107-13. PubMed ID: 19210206
    [Abstract] [Full Text] [Related]

  • 13. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E, Bonadei I, D'Aloia A, Del Magro F, Piovanelli B, Bontempi L, Curnis A, Dei Cas L.
    Minerva Med; 2011 Oct 29; 102(5):373-9. PubMed ID: 22193347
    [Abstract] [Full Text] [Related]

  • 14. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov 29; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 15. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R, Ceconi C.
    Expert Rev Cardiovasc Ther; 2011 Aug 29; 9(8):959-73. PubMed ID: 21878041
    [Abstract] [Full Text] [Related]

  • 16. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009 Aug 29; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
    Borer JS, Tardif JC.
    Am J Cardiol; 2010 Jan 01; 105(1):29-35. PubMed ID: 20102886
    [Abstract] [Full Text] [Related]

  • 18. I(f) inhibition in cardiovascular diseases.
    Thollon C, Vilaine JP.
    Adv Pharmacol; 2010 Jan 01; 59():53-92. PubMed ID: 20933199
    [Abstract] [Full Text] [Related]

  • 19. Ivabradine: new drug. Best avoided in stable angina.
    Prescrire Int; 2007 Apr 01; 16(88):53-6. PubMed ID: 17458043
    [Abstract] [Full Text] [Related]

  • 20. Heart rate in coronary syndromes and heart failure.
    Orso F, Baldasseroni S, Maggioni AP.
    Prog Cardiovasc Dis; 2009 Apr 01; 52(1):38-45. PubMed ID: 19615492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.